

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**ESSEX BIO-TECHNOLOGY LIMITED**

**億勝生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1061)**

**VOLUNTARY ANNOUNCEMENT**

**UNAUDITED OPERATING STATISTICS  
FOR THE FOUR MONTHS ENDED 30 APRIL 2021**

The board of directors (the “**Board**”) of Essex Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces certain unaudited operating statistics of the Group for the four months ended 30 April 2021 and the comparative figures for the corresponding period in 2020.

As disclosed in the annual report of the Company for the year ended 31 December 2020, the revenue of the Group has been recovering to nearing the pre-COVID-19 level from the third quarter of 2020 following the resumption of clinical operations in hospitals to normalcy since September 2020 in the People’s Republic of China. Such trend of financial performance of the Group continues in the first four months of 2021.

For the four months ended 30 April 2021, the Group recorded an unaudited revenue of approximately HK\$438 million against approximately HK\$128 million for the corresponding period in 2020, an increase of 242.2%. The results for the first four months in 2021 show that the Group’s business is resilient and continues to operate at the pre-COVID-19 level.

The information contained in this announcement is based on the Board’s preliminary assessment after reviewing the unaudited consolidated management accounts of the Group for the four months ended 30 April 2021 and the information currently available to the management of the Group, which have not been reviewed or audited by the independent auditors and/or the audit committee of the Company. The information contained in this announcement do not constitute, represent or indicate the Group’s total revenue or full financial performance and the information contained in this announcement may be subject to change and adjustment.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

On behalf of the Board  
**Essex Bio-Technology Limited**  
**Ngiam Mia Je Patrick**  
*Chairman*

Hong Kong, 17 May 2021

*Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou, Mr. Ngiam Hian Leng Malcolm and Ms. Yau Lai Man. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.*